Pharmaceuticals – The Next Stop For Value-Based Pricing

Lately headlines involving pharmaceuticals have become more commonplace — a few recent stories from the OPEN MINDS Weekly News Wire reminded me of the many new developments in this area. Most recently, these developments focused on the opioid crisis (see FDA Approves Six-Month Implant For Opioid Addiction Treatment), new research incubators (see Janssen Launches New Research Platforms For Disease Prevention), and most recently, the expansion of value-based reimbursement models for medications. Just as value-based care is shaping service delivery in health and human services, we're seeing new value-based models being applied to medication management.

Last year . . .